Education
About Us
Working with TipRanks
Follow Us
Immuno-Biological Laboratories Co., Ltd. (JP:4570)
:4570
4570 Stock Chart & Stats
¥1404.00
¥18.00(3.96%)
At close: 4:00 PM EST
¥1404.00
¥18.00(3.96%)
Day’s Range― - ―
52-Week Range¥356.00 - ¥3,820.00
Previous CloseN/A
Volume75.00K
Average Volume (3M)23.51K
Market Cap
¥14.71B
Enterprise Value¥14.00B
Total Cash (Recent Filing)¥903.75M
Total Debt (Recent Filing)¥196.94M
Price to Earnings (P/E)41.6
Beta0.93
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.44
Shares Outstanding9,314,590
10 Day Avg. Volume28,690
30 Day Avg. Volume23,506
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)2.95
Price to Sales (P/S)4.61
P/FCF Ratio36.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Margins And Profitability TurnaroundHigh gross margin (64.8%) and a 25.7% net margin reflect durable product-level pricing power and improved operational efficiency. Sustained margins increase resilience to volume swings, enable internal funding of assay R&D and commercialization, and support long-term profitability.
Conservative Balance Sheet And Healthy ROEA low debt-to-equity ratio (0.13) and high equity ratio (~82%) combined with a 16.4% ROE indicate low financial leverage and efficient equity deployment. This provides strategic optionality for R&D spend, targeted M&A or weathering downturns without materially raising financing risk.
Improving Cash Generation And ConversionRising operating cash flow and an OCF-to-net-income ratio of 0.74 show improving cash conversion and positive free cash flow trends. Reliable internal cash generation reduces reliance on external financing and supports continued investment in production capacity and new assay development.
Bears Say
Small Organizational ScaleA headcount of only 57 suggests limited internal capacity for scaling manufacturing, commercial expansion and global distribution. Small scale raises execution risk on large contracts, increases reliance on key personnel, and can slow multi-market rollouts over the medium term.
Moderate Revenue GrowthRevenue growth near 13% is positive but modest for a specialized life-science supplier. In a competitive reagents and diagnostics market, slower top-line expansion can limit reinvestment capacity, reduce market-share momentum versus larger peers, and constrain long-term scale benefits.
Limited Public Guidance And Disclosed Corporate EventsThe absence of earnings-call highlights and no disclosed corporate events indicates limited public guidance and fewer visible strategic updates. Reduced transparency makes it harder for stakeholders to assess management priorities, long-term capital allocation and execution risks over time.
4570 FAQ
What was Immuno-Biological Laboratories Co., Ltd.’s price range in the past 12 months?
Immuno-Biological Laboratories Co., Ltd. lowest stock price was ¥356.00 and its highest was ¥3820.00 in the past 12 months.
What is Immuno-Biological Laboratories Co., Ltd.’s market cap?
Immuno-Biological Laboratories Co., Ltd.’s market cap is ¥14.71B.
When is Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date?
Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 91 days.
How were Immuno-Biological Laboratories Co., Ltd.’s earnings last quarter?
Immuno-Biological Laboratories Co., Ltd. released its earnings results on Feb 12, 2026. The company reported ¥11.44 earnings per share for the quarter, beating the consensus estimate of N/A by ¥11.44.
Is Immuno-Biological Laboratories Co., Ltd. overvalued?
According to Wall Street analysts Immuno-Biological Laboratories Co., Ltd.’s price is currently Overvalued.
Does Immuno-Biological Laboratories Co., Ltd. pay dividends?
Immuno-Biological Laboratories Co., Ltd. pays a Notavailable dividend of ¥6 which represents an annual dividend yield of N/A. See more information on Immuno-Biological Laboratories Co., Ltd. dividends here
What is Immuno-Biological Laboratories Co., Ltd.’s EPS estimate?
Immuno-Biological Laboratories Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immuno-Biological Laboratories Co., Ltd. have?
Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding.
What happened to Immuno-Biological Laboratories Co., Ltd.’s price movement after its last earnings report?
Immuno-Biological Laboratories Co., Ltd. reported an EPS of ¥11.44 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.396%.
Which hedge fund is a major shareholder of Immuno-Biological Laboratories Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4570
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuno-Biological Laboratories Co., Ltd.
Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.
Technical Analysis
Ribomic, Inc.
―
BrightPath Biotherapeutics Co.Ltd.
―
Delta-Fly Pharma, Inc.
―
FunPep Company Limited
―
Kringle Pharma, Inc.
―